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Abstract
Background: It has been previously reported that plasma
osteopontin (OPN) concentrations are increased in cardio-
vascular disorders. The goal of the present study was to
determine plasma OPN concentrations in healthy pregnant
women and preeclamptic patients, and to investigate their
relationship to the clinical characteristics of the study sub-
jects and to markers of inflammation wC-reactive protein
(CRP)x, endothelial activation wvon Willebrand factor antigen
(VWF:Ag)x or endothelial injury (fibronectin), oxidative
stress wmalondialdehyde (MDA)x and trophoblast debris (cell-
free fetal DNA).
Methods: Forty-four patients with preeclampsia and 44
healthy pregnant women matched for age and gestational age
were involved in this case-control study. Plasma OPN con-
centrations were measured with ELISA. Serum CRP concen-
trations were determined with an autoanalyzer using the
manufacturer’s reagents. Plasma VWF:Ag was quantified by
ELISA, while plasma fibronectin concentrations were meas-
ured by nephelometry. Plasma MDA concentrations were
estimated by the thiobarbituric acid-based colorimetric assay.
The amount of cell-free fetal DNA in maternal plasma was
determined by quantitative real-time PCR analysis of the sex-
determining region Y (SRY) gene. For statistical analyses,
non-parametric methods were applied.
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Results: Serum levels of CRP, as well as plasma concentra-
tions of VWF:Ag, fibronectin, MDA and cell-free fetal DNA
were significantly higher in preeclamptic patients than in
healthy pregnant women. There was no significant difference
in plasma OPN concentrations between controls and the pre-
eclamptic group. However, preeclamptic patients with plas-
ma fibronectin concentrations in the upper quartile had
significantly higher plasma OPN concentrations than those
below the 75th percentile, as well as healthy pregnant women
wmedian (interquartile range): 9.38 (8.10–11.99) vs. 7.54
(6.31–9.40) and 7.40 (6.51–8.80) ng/mL, respectively,
p-0.05 for bothx. Furthermore, in preeclamptic patients,
plasma OPN concentrations showed a significant positive
linear association with plasma fibronectin (Spearman
Rs0.38, standardized regression coefficient (b)s0.41,
p-0.05 for both).
Conclusions: Plasma OPN concentrations are increased in
preeclamptic patients with extensive endothelial injury. How-
ever, further studies are warranted to explore the relationship
between OPN and endothelial damage.
Clin Chem Lab Med 2010;48:181–7.
Keywords: endothelial injury; fibronectin; osteopontin; pre-
eclampsia; pregnancy.
Introduction
Preeclampsia is a severe complication of human pregnancy
with a worldwide incidence of 2%–10% (1). It is one of the
leading causes of maternal, as well as perinatal morbidity
and mortality, even in developed countries. Despite intensive
research efforts, the etiology and pathogenesis of preeclamp-
sia are not completely understood. Increasing evidence
suggests that an excessive maternal systemic inflammatory
response to pregnancy with systemic oxidative stress and
resultant endothelial damage plays a crucial role in the
pathogenesis of the disease (2, 3). The development of pre-
eclampsia is influenced by both genetic and environmental
risk factors, suggesting a multifactorial inheritance (4–9).
Osteopontin (OPN) is a 70-kDa glycoprotein which was
demonstrated to be present in the endometrium (10), where
it is indicative of a decidualization-like process during preg-
nancy. It is involved in adhesion and signal transduction at
the uterine-placental interface (11). OPN has also been found
in the trophoblast of the human placenta, and it can enhance
the invasiveness of trophoblast cells in vitro (12). Further-
more, OPN is expressed by endothelial, vascular smooth
muscle cells (VSMCs) and immune cells (13, 14), and it acts
as a proinflammatory Th1 type cytokine (15). The role of
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OPN is considered in several physiological and pathological
states, such as embryo implantation, placentation, chronic
inflammation and autoimmune diseases (11, 16–20).
Local overexpression and elevated plasma concentrations
of OPN were observed in aortic, coronary and carotid ath-
erosclerosis (21–24). It was shown that OPN is a component
of atherosclerotic plaques and mediates arterial neointima
formation as well as dystrophic calcification in the vessel
walls (25). These indicate the significance of OPN in the
maintenance of chronic inflammation and in plaque forma-
tion in atherosclerosis. Interestingly, atherosclerosis shares
many risk factors (obesity, dyslipidemia, insulin resistance)
and pathogenetic features (inflammation, oxidative stress and
endothelial injury) with preeclampsia. In addition, women
who develop preeclampsia are at an increased risk of athero-
sclerotic cardiovascular disorders later in life (26).
In the present study, we measured plasma OPN concen-
trations in healthy pregnant women and patients with pre-
eclampsia. Given that plasma OPN has recently been
observed to be increased in atherosclerotic cardiovascular
disorders and that atherosclerosis shares many common
pathophysiological mechanisms with preeclampsia, including
inflammation and oxidative stress in which OPN has been
implicated, we hypothesized that plasma OPN concentrations
are increased in preeclampsia. To our knowledge, this is the
first report on plasma OPN concentrations in preeclampsia.
We determined several markers of processes involved in
the pathogenesis of preeclampsia, such as C-reactive protein
(CRP), von Willebrand factor antigen (VWF:Ag), fibronec-
tin, malondialdehyde (MDA) and cell-free fetal DNA.
Increased CRP concentrations represent systemic inflamma-
tion characteristic of preeclampsia (27, 28). Plasma VWF:Ag
concentrations indicate endothelial activation (29), while
plasma fibronectin concentration is a reliable marker of
endothelial injury in preeclampsia (30–33). The latter was
shown to reflect the severity, organ involvement and com-
plications of the disorder (34, 35). Additionally, fibronectin
was found to predict the development of preeclampsia
both in normotensive and in hypertensive pregnant women
(34, 36, 37). Plasma concentrations of MDA also were dem-
onstrated to be increased in preeclampsia as a consequence
of placental and systemic oxidative stress (33, 38–40). Tro-
phoblast particles can frequently be detected in the maternal
peripheral circulation in preeclampsia. The mass of this tro-
phoblast debris can be estimated by measurement of copies
of cell-free fetal DNA in the maternal blood. Significant
increases were observed in preeclampsia compared to normal
pregnancies before and after the onset of clinical symptoms
(41–44). We also examined whether these laboratory mark-
ers, as well as the clinical features of the study subjects, were
related to OPN concentrations in our study groups.
Materials and methods
Study participants
Our study was designed using a case-control approach. Forty-four
preeclamptic patients (19 with severe disease) and 44 normotensive
(blood pressure -140 mm Hg systolic and -90 mm Hg diastolic),
healthy pregnant women with uncomplicated pregnancies matched
for age and gestational age were involved in the study. The sample
size provided sufficient statistical power ()80% at a Type I error
rate of 0.05) to detect differences in plasma OPN concentrations
between cases and controls which have been observed previously
in coronary artery disease (CAD) (22). The study participants were
enrolled in the First Department of Obstetrics and Gynecology and
in the Department of Obstetrics and Gynecology of Ku´tvo¨lgyi Clin-
ical Center, at the Semmelweis University, Budapest, Hungary. All
women were Caucasian and resided in the same geographic area in
Hungary. Exclusion criteria were multifetal gestation, chronic hyper-
tension, diabetes mellitus, autoimmune disease, angiopathy, renal
disorder, maternal or fetal infection and fetal congenital anomaly.
The women were fasting, none were in active labor, and none had
rupture of membranes.
Preeclampsia was defined as increased blood pressure (G140
mm Hg systolic or G90 mm Hg diastolic on G2 occasions at least
6 h apart) that occurred after 20 weeks of gestation in a woman
with previously normal blood pressure, accompanied by proteinuria
(G0.3 g/24 h). Blood pressure returned to normal by 12 weeks
postpartum in each study patient with preeclampsia. Preeclampsia
was regarded as severe if any of the following criteria was present:
blood pressure G160 mm Hg systolic or G110 mm Hg diastolic,
or proteinuria G5 g/24 h. Pregnant women with HELLP syndrome
(hemolysis, elevated liver enzymes, and low platelet count) were
not enrolled in this study. Fetal growth restriction was diagnosed if
the fetal birth weight was below the 10th percentile for gestational
age and gender, based on Hungarian birth weight percentiles (45).
The study protocol was approved by the Regional and Institu-
tional Committee of Science and Research Ethics of the Semmel-
weis University, and written informed consent was obtained from
each patient. The study was conducted in accordance with the
Declaration of Helsinki.
Biological samples
Maternal blood samples were obtained from the antecubital vein
into plain tubes, EDTA or sodium citrate, and then centrifuged at
room temperature with a relative centrifugal force of 3000 g for
10 min. The aliquots of serum and plasma were stored at –808C
until the analyses. To determine OPN, fibronectin, MDA and cell-
free fetal DNA concentrations, we used EDTA-anticoagulated plas-
ma samples, while VWF:Ag was measured in citrated plasma.
Laboratory methods
Quantitative detection of plasma OPN was performed using the
Human Osteopontin ELISA assay (DRG International, Inc., Moun-
tainside, NJ, USA, Cat. No. EIA-3116) according to the manufac-
turer’s protocol. The sensitivity of the assay was 0.11 ng/mL, and
the intra-/inter-assay coefficient of variation (CV) was -5%/
-10%, respectively. Serum CRP concentrations were determined
using the Cobas Integra 800 (Roche, Mannheim, Germany) and the
manufacturer’s kits. The lower detection limit was 0.07 mg/L. Plas-
ma VWF:Ag concentrations were quantified using ELISA (Dako-
patts, Glostrup, Denmark), while plasma fibronectin concentrations
were measured by nephelometry (Dade Behring, Marburg, Germa-
ny) according to the manufacturer’s instructions. The sensitivities of
these assays were 6.16% and 0.01 g/L, respectively.
Concentrations of thiobarbituric acid reactive substances in blood
plasma were estimated according to the method of Placer et al. (46).
The assay procedure was based on the addition of 2-thiobarbituric
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Table 1 Clinical characteristics of normotensive, healthy pregnant women and patients with preeclampsia.
Controls (ns44) Preeclampsia Statistical
(ns44) significance
(p-value)
Age, years 30.5 (28–32.5) 29 (26–32.5) NS
BMI at blood draw, kg/m2 26.1 (24.3–28.2) 29.9 (25.7–34.0) -0.05
Smokers 0 (0%) 3 (6.8%) NS
Primiparas 27 (61.4%) 28 (63.6%) NS
Systolic blood pressure, mm Hg 112.5 (110–120) 169.5 (160–180) -0.001
Diastolic blood pressure, mm Hg 70 (60–80) 100 (100–110) -0.001
Gestational age at blood draw, weeks 36 (36–37) 37 (35.5–38) NS
Gestational age at delivery, weeks 39 (38–40) 38 (36–38) -0.001
Fetal birth weight, g 3450 (3025–3550) 2900 (2225–3350) -0.001
Fetal growth restriction 0 (0%) 11 (25.0%) -0.001
Data are presented as median (25th–75th percentile) for continuous variables and as number (%) for categorical variables. NS, not significant;
BMI, body mass index.
acid with MDA as the end-product of lipid peroxidation, under acid-
ic conditions (pHs2.0) and high temperature (1008C). The assay
was calibrated using 1,1,3,3-tetraethoxy-propane (Fluka, Buchs,
Switzerland) as a source of MDA. Concentrations of blood plasma
MDA were calculated as nmol/mL of plasma. The limit of quanti-
fication was 0.82 nmol/mL.
The amount of cell-free fetal DNA in maternal plasma was deter-
mined in patients with male newborns by quantitative real-time
PCR analysis of the sex determining region Y (SRY) gene, as we
described previously (47). Briefly, DNA was extracted from 400 mL
EDTA anticoagulated plasma with the High Pure PCR Template
Preparation Kit (Roche Diagnostics, Mannheim, Germany) accord-
ing to the manufacturer’s protocol. The DNA was eluted in 50 mL
of elution buffer solution, and 1 mL was used as a template for the
PCR reaction. For the SYBR Green real-time PCR analysis, we used
a LightCycler 1.0 System (Roche Diagnostics, Mannheim, Germa-
ny). Circulating male fetal DNA was detected with the following
primers for the SRY gene: forward 59-GGC AAC GTC CAG GAT
AGA GTG A-39, reverse 59-TGC TGA TCT CTG AGT TTC GCA
TT-39. The PCR analysis was performed in 10 mL reaction volumes
containing 1 mL DNA, 2.5 pmol/L of each amplification primer,
1 mL of DNA Master SYBR Green I mix (LightCycler FastStart
DNA Master SYBR Green I kit: Taq polymerase, dNTP, MgCl2),
and 6 mL of nuclease free water. The PCR was performed in 40
cycles under the following conditions: initial denaturation 8 min at
958C, 5 s denaturation at 958C, 10 s annealing at 608C, 15 s exten-
sion at 728C, cooling to 48C. To determine the number of copies of
circulating DNA present in the plasma sample, a standard dilution
curve with a known concentration of male genomic DNA was used.
All samples were analyzed in duplicate and scored in blinded fash-
ion. The detection limit was 1.5 pg/L.
Statistical analysis
Normal distribution of continuous variables was assessed using the
Shapiro-Wilk’s W-test. As the continuous variables were not nor-
mally distributed, non-parametric statistical methods were used. To
compare continuous variables between two groups, the Mann-Whit-
ney U-test was applied. Fisher’s exact and Pearson’s x2-tests were
performed to compare categorical variables between groups. The
Spearman rank order correlation was performed to calculate corre-
lation coefficients. As plasma OPN concentrations showed a skewed
distribution, multiple linear regression analysis was performed and
the scatterplot was created with logarithmically transformed data.
Statistical analyses were carried out using the following software:
STATISTICA (version 8.0; StatSoft, Inc., Tulsa, OK, USA) and Sta-
tistical Package for the Social Sciences (version 15.0 for Windows;
SPSS, Inc., Chicago, IL, USA). For all statistical analyses, p-0.05
was considered statistically significant.
Data are reported as median (interquartile range) for continuous
variables and as number (percent) for categorical variables.
Results
Patient characteristics
The clinical characteristics of the study participants are
described in Table 1. There were no statistically significant
differences in terms of maternal age and gestational age at
blood collection and the percentage of smokers and primi-
paras between the two study groups. The body mass index
(BMI) and systolic and diastolic blood pressures were sig-
nificantly higher, while the gestational age at delivery and
the fetal birth weight were significantly lower in the pre-
eclamptic group compared with the control group. Fetal
growth restriction was absent in control subjects, whereas the
frequency of this condition was 25.0% in the preeclamptic
group.
Laboratory parameters
As shown in Table 2, serum concentrations of CRP as well
as of plasma concentrations of VWF antigen, fibronectin,
MDA and cell-free fetal DNA were significantly higher in
patients with preeclampsia compared with normotensive,
healthy pregnant women. However, there was no significant
difference in plasma OPN concentrations between the control
and the preeclamptic group (Table 2).
We investigated whether clinical characteristics and labo-
ratory parameters of the study participants were related to
plasma OPN concentrations by calculating the Spearman
rank order correlation coefficients (continuous variables) or
by the Mann-Whitney U-test (categorical variables). As
shown in Figure 1, in preeclamptic patients, plasma OPN
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Table 2 Laboratory parameters of normotensive, healthy pregnant women and patients with preeclampsia.
Controls (ns44) Preeclampsia (ns44) Statistical
significance
(p-value)
Serum CRP, mg/L 3.59 (1.68–7.40) 6.11 (1.92–12.12) -0.05
Plasma VWF:Ag, % 148.4 (106.6–199.0) 183.0 (128.7–242.8) -0.05
Plasma fibronectin, g/L 0.36 (0.32–0.47) 0.58 (0.39–0.82) -0.001
Plasma malondialdehyde, nmol/mL 13.13 (8.38–18.61) 18.17 (14.98–20.31) -0.05
Plasma fetal DNA, pg/mL 0.005 (0.0–0.178) 0.065 (0.034–0.267) -0.05
Plasma osteopontin, ng/mL 7.40 (6.51–8.80) 7.77 (6.60–9.67) NS
Data are presented as median (25th–75th percentile). NS, not significant; CRP, C-reactive protein; VWF:Ag, von Willebrand factor antigen.
Figure 1 Scatterplot with linear fit and regression line of loga-
rithmically transformed values of plasma osteopontin vs. plasma
fibronectin concentrations in preeclamptic patients (Spearman
Rs0.38, standardized regression coefficient (b)s0.41, p-0.05 for
both).
Figure 2 Plasma osteopontin concentrations in preeclamptic
patients with plasma fibronectin in the upper quartile (G0.82 g/L,
ns13), below the 75th percentile (-0.82 g/L, ns31) and in
healthy pregnant women (ns44).
Middle line: median; box: interquartile range; Whisker: range
(excluding outliers); NS, not significant.
showed a significant positive linear association with plasma
fibronectin concentrations (Spearman Rs0.38, p-0.05),
even after adjustment for BMI in multiple linear regression
analysis (standardized regression coefficient (b)s0.41,
p-0.05). However, no other relationship was found between
clinical features and the measured laboratory parameters
(serum CRP, plasma VWF:Ag, MDA and cell-free fetal
DNA) of the study subjects and plasma OPN concentrations
in normotensive, healthy pregnant women, or in preeclamptic
patients (data not shown).
Given the association between plasma OPN and fibro-
nectin concentrations in preeclampsia, we divided our
preeclamptic group on the basis of plasma fibronectin con-
centrations. Preeclamptic patients with plasma fibronectin in
the upper quartile (G0.82 g/L) had significantly higher plas-
ma OPN concentrations than those below the 75th percentile
(-0.82 g/L), as well as healthy pregnant women wmedian
(interquartile range): 9.38 (8.10–11.99) vs. 7.54 (6.31–9.40)
and 7.40 (6.51–8.80) ng/mL, respectively, p-0.05 for both;
Figure 2x. This subgroup of patients with preeclampsia was
also characterized by more frequent occurrence of the severe
form of the disease w9 of 13 (69.2%) vs. 10 of 31 (32.3%),
p-0.05x, as well as by significantly higher diastolic blood
pressure wmedian (interquartile range): 110 (100–120) vs.
100 (98–110) mm Hg, p-0.05x, as compared to preeclamp-
tic women with fibronectin concentrations in the lower three
quartiles.
Discussion
In this study, we found that preeclamptic patients with exten-
sive endothelial injury had significantly higher plasma OPN
concentrations compared to those without extensive injury as
well as healthy pregnant women. In addition, plasma OPN
showed a significant positive linear association with plasma
fibronectin concentrations in preeclampsia.
Several clinical surveys reported an association between
altered OPN concentrations and cardiovascular diseases.
Ohmori et al. observed that OPN plasma concentrations cor-
relate with the extent of CAD (22). Coskun et al. found high-
er OPN concentrations in patients with acute coronary
syndrome compared to patients with stable angina (48). Soe-
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jima et al. showed that OPN production in peripheral T cells
is increased in relation to the severity of heart failure (49).
OPN presumably plays an important role in the development
of atherosclerosis (25, 50), acting in two different ways.
First, OPN participates in the maintenance of chronic sys-
temic inflammation through its cytokine and chemokine
effects (17, 51). Second, Georgiadou et al. showed that in
blood samples of patients with CAD, OPN concentrations
are independently associated with MDA concentrations; a
well-known biomarker of lipid peroxidation and oxidative
stress (23). Systemic inflammation with an excessive Th1
response and oxidative stress also are essential factors in the
pathogenesis of preeclampsia (39, 52). However, despite
these facts, we could not establish any association between
OPN concentrations and the markers of inflammation (CRP)
or oxidative stress (MDA) in preeclampsia. It is possible that
overproduction of OPN by activated peripheral blood mono-
nuclear cells was masked by its rapid consumption during
the exaggerated inflammatory processes in preeclampsia.
The extravillous trophoblasts of the human placenta also
express OPN, which regulates the invasiveness of these cells
(12). Gabinskaya et al. studied human placentas with immu-
nostaining. They showed that after the 30th gestational week,
OPN is only present in cytotrophoblasts of preeclamptic pla-
centas, but not in healthy ones (53). It was previously report-
ed that a significantly higher amount of trophoblast debris
can be found in the maternal circulation in preeclampsia
compared to women with a normal pregnancy (41, 42, 54).
Based on these observations, we examined the association
between the concentrations of circulating fetal DNA as a
marker of trophoblast debris, and OPN in maternal blood.
However, we could not detect any relationship. Thus, we
hypothesize that OPN can have only a local placental effect
in preeclampsia.
Endothelial activation and injury play an important role in
the pathogenesis of atherosclerosis, and OPN may participate
in this process (13). Like atherosclerosis, preeclampsia is
characterized by endothelial activation and injury. Therefore,
we investigated whether plasma OPN concentrations are
related to markers of endothelial activation (VWF:Ag), or
endothelial damage (fibronectin) in preeclampsia. However,
there was no relationship between VWF:Ag and OPN.
Instead, we found a positive linear association between fibro-
nectin and OPN concentrations. Furthermore, OPN concen-
trations were significantly higher in preeclamptic patients
whose fibronectin concentrations were in the upper quartile
compared to patients with preeclampsia with fibronectin
below the 75th percentile, as well as to healthy pregnant
women. In addition to having increased OPN concentrations,
preeclamptic women with high fibronectin concentrations
had a more severe form of the disease. OPN and fibronectin
are components of the extracellular matrix and both contain
an arginine-glycine-aspartic acid (RGD) sequence, which can
bind integrin molecules. Interestingly, intermolecular cross-
linking can be formed between these two proteins (55).
Therefore, we suppose that OPN may be released from the
vessel wall into the peripheral circulation together with fibro-
nectin in cases of extensive endothelial injury. This might
explain the observed association between plasma OPN and
fibronectin concentrations in preeclampsia. However, the
relationship of OPN to other markers of endothelial dys-
function or injury in preeclampsia, such as circulating endo-
thelial cells (56), thrombomodulin (57), endothelin-1 and
E-selectin (33) should be investigated in future studies to
confirm our findings.
Preeclampsia is a heterogeneous syndrome with various
clinical manifestations. We identified a subgroup of pre-
eclamptic patients with significantly increased plasma OPN
concentrations. Defining more homogeneous study popula-
tions in this way may help to understand the complex eti-
ology and pathogenesis of this multifactorial disorder.
The limitations of our study are its case-control design and
the relatively low number of patients involved. Also, we did
not compare OPN production of peripheral blood mononu-
clear cells between cases and controls.
In conclusion, plasma OPN concentrations are increased
in preeclamptic patients with extensive endothelial injury.
However, further studies are warranted to explore the asso-
ciation of OPN with endothelial damage.
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